NTRK2 and glaucoma: We chose to develop and test a novel gene therapy construct involving brain-derived neurotrophic factor (BDNF) and its cognate receptor, tropomyosin-related receptor kinase-B (TrkB)8–10, whose expression and activation are impaired in rodent11–16, dog17, and primate18 models of glaucoma.